Frankfurt am Main, Germany

Hans Ludwig Schäfer


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Hans Ludwig Schäfer

Introduction

Hans Ludwig Schäfer is a notable inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of medicine, particularly in the area of cardiovascular health. With a total of 2 patents, his work focuses on innovative methods to combat atherosclerosis.

Latest Patents

Schäfer's latest patents include groundbreaking methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody. This invention provides methods and compositions aimed at inhibiting atherosclerotic plaque formation in subjects at risk of developing this condition. The methods involve selecting a subject and administering a pharmaceutical composition that includes a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, specifically an anti-PCSK9 antibody or antigen binding protein. Another patent focuses on similar methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9, reinforcing the importance of this research in cardiovascular health.

Career Highlights

Throughout his career, Hans Ludwig Schäfer has worked with prominent companies in the biotechnology sector, including Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to medical challenges.

Collaborations

Schäfer has collaborated with notable professionals in his field, including William J. Sasiela and Viktoria Gusarova. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Hans Ludwig Schäfer's contributions to the field of medicine through his innovative patents demonstrate his commitment to improving cardiovascular health. His work continues to influence the development of effective treatments for atherosclerosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…